1190 / 1578
Neurocognitive decline after WBRT
Reference
Patients
Dose
PCI
Baseline
Abnormalities
(free)
Cognitive
impairment after
a year
Arrigada
294; SCLC
24 Gy
Control: 44%
PCI: 50%
Control:36%
PCI: 30%
Gregor
314; SCLC
8-36Gy
PASAT
Control: 17%
PCI:31%
Wolfson
264; SCLC
25 vs 36Gy
25Gy: 62%
36Gy: 85%
Le Pechoux
720; SCLC
25 vs 36Gy
25Gy :35%
36Gy: 47%
Sun
340; SCLC
30Gy
Control:12%
PCI: 41%
•
At least one neurocognitve dysfunction could be observed
after WBRT
•
Grade of impairment depends of the dose